NVST Envista Holdings Corp

Wall Street Zen has downgraded Envista (NYSE:NVST) from a "strong-buy" to a "buy" rating, though the overall analyst consensus remains a "Hold" with an average price target of $21.77. Despite Envista beating Q3 earnings and revenue estimates, the stock is trading around $22 with a high P/E ratio of 247.47. Several other analysts have also provided varying ratings and price targets for the company recently.

Envista Holdings (NVST) has seen solid share price gains recently, driven by improving earnings and steady dental equipment demand. While Simply Wall St's narrative pegs the stock as about right in value at $22.15, their DCF model suggests a modest 2.5% undervaluation. Investors should consider potential risks like Chinese pricing reforms, but the company's cost reductions and operational optimizations forecast continued margin improvement.

DeepCurrents Investment Group LLC significantly reduced its stake in Envista Holdings Corporation (NYSE:NVST) by 99.0% in Q2, now holding 69,831 shares valued at $1.36 million. Envista has a consensus "Hold" rating from analysts with an average price target of $21.54, and the company recently beat earnings estimates with EPS of $0.32 and revenue of $669.9 million. The stock currently trades near its 52-week high, and future analyst forecasts project an EPS of 1 for the current year.

Stifel has reiterated a Buy rating on Envista Holdings Corp. (NYSE:NVST), citing an improving dental market and the company's strong financial health and aggressive share buybacks. Envista's management describes the market as "stable plus," with accelerated growth in 2025 across clear aligners and diagnostics, and revenue growth of 4.73% over the last twelve months. The company's upbeat outlook is supported by a strong liquidity position and recent positive earnings reports.

Envista Holdings (NYSE: NVST) shares rose by 3.2% after Barclays initiated coverage with an 'Overweight' rating and a $24 price target, indicating a positive outlook. This new coverage boosted investor confidence, although the stock's volatility suggests the market views this as meaningful but not fundamentally altering its perception of the business. Envista is up 8% year-to-date and is trading near its 52-week high.

Shares of dental products company Envista Holdings (NYSE:NVST) jumped 3.2% after Barclays initiated coverage with an 'Overweight' rating and a $24 price target. This positive analyst outlook, coupled with recent hopes for an interest rate cut, has contributed to the stock's year-to-date gain of 8%. Despite some volatility, today's move is seen as meaningful for the company.